Vaccination with ACAM2000
ApprovedCompleted 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Smallpox Vaccine Adverse Reaction
Conditions
Smallpox Vaccine Adverse Reaction
Trial Timeline
Sep 1, 2015 → Aug 1, 2021
NCT ID
NCT02443623About Vaccination with ACAM2000
Vaccination with ACAM2000 is a approved stage product being developed by Emergent BioSolutions for Smallpox Vaccine Adverse Reaction. The current trial status is completed. This product is registered under clinical trial identifier NCT02443623. Target conditions include Smallpox Vaccine Adverse Reaction.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02443623 | Approved | Completed |
Competing Products
20 competing products in Smallpox Vaccine Adverse Reaction